RxDoctor Payments Data

Edward King, MD

Urology · Ocala, FLNPI 1205834728

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.3%), ownership interests and travel and lodging — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by Laser Specialty Medical, LLC at 25.4% of the total. Reporting peaked in 2022 at $8,763 and has fallen 59.1% since, to $3,588 in 2025. Among urology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$37,349in general payments, 2019–2025

Across 607 payments — averaging $61.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Laser Specialty Medical, LLC$10K
  • SN Holdings, LLC$5K
  • Medtronic$3K
  • Coloplast$3K
  • Johnson & Johnson$3K
  • Teleflex LLC$2K
  • plus $13K from 52 others
$38,657in research payments, 2019–2025

Across 12 payments — averaging $3221.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dendreon Pharmaceuticals LLC$39K

What the payments were for

  • Consulting fees$1,0103%
  • Speaking & faculty fees$1,0133%
  • Travel & lodging$6,83018%
  • Food & beverage$18,41349%
  • Education$5832%
  • Ownership interest$9,50025%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Laser Specialty Medical, LLC3$9,500
SN Holdings, LLC8$4,947
Medtronic(2 entities)31$2,677
Coloplast41$2,609
Johnson & Johnson55$2,600
Teleflex LLC23$1,679
Astellas Pharma US Inc55$1,678
Dendreon Pharmaceuticals LLC20$1,536
Myriad Genetic Laboratories, Inc.39$1,083
Pfizer46$976
Ferring Pharmaceuticals Inc.15$697
Bayer28$695
AstraZeneca18$615
Procept Biorobotics Corporation6$606
Telix Pharmaceuticals12$555
Sumitomo Pharma America, Inc.21$434
Myovant Sciences Inc.18$394
Antares Pharma, Inc.5$286
Tolmar Pharmaceuticals, Inc.15$283
AbbVie(2 entities)13$223
Sun Pharmaceutical Industries Inc.12$220
Novartis10$218
Boston Scientific9$207
Axonics, Inc.10$205
Bioprotect Medical, Inc.5$195
Endo Pharmaceuticals Inc.10$193
Blue Earth Diagnostics7$153
Laborie Medical Technologies Corp.3$148
Tempus AI, Inc2$144
Urovant Sciences Inc7$129
Amgen8$128
EMD Serono, Inc.1$125
Merck5$104
Angiodynamics, Inc.1$103
180 Medical, Inc.4$96
Foundation Medicine, Inc.4$93
Agiliti Surgical, Inc.1$93
Urogen Pharma, Inc.4$92
Accord Healthcare, Inc.4$83
Integra Lifesciences Corporation1$78
Verity Pharmaceuticals Inc.4$61
Dentsply IH Inc.3$48
Metuchen Pharmaceuticals2$41
Pacira Pharmaceuticals Incorporated2$30
Olympus America Inc.2$29
Smith+Nephew2$27
Calyxo, Inc.1$26
Photocure Inc1$26
C. R. Bard, Inc. & Subsidiaries1$25
Alnylam Pharmaceuticals Inc.1$23
Tolmar, Inc.1$21
Immunitybio, Inc.1$20
Progenics Pharmaceuticals, Inc.1$20
Profound Medical Corp.1$16
Acerus Pharmaceuticals Corporation1$16
Rochester Medical Corporation1$15
Cardinal Health 414 LLC1$15
Cook Medical LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,349 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.

See all urology providers in Florida →

Medicare billing

Part B allowed, 2024
$1,010,920
Medicare patients
1,374
Services billed
48,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide199$2,724,643
ErleadaApalutamide54$826,339
OrgovyxRelugolix129$339,146
NubeqaDarolutamide21$275,104
MyrbetriqMirabegron221$209,231
GemtesaVibegron47$41,763
Abiraterone Acetate30$32,265
Testosterone105$22,567
Tamsulosin Hcl899$12,758
Oxybutynin Chloride ErOxybutynin Chloride348$9,408
Methenamine Hippurate120$9,115
Testosterone Cypionate77$5,454
Tadalafil67$5,390
Tolterodine Tartrate ErTolterodine Tartrate38$4,488
Finasteride297$4,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,678$2,933,874420 claims
Johnson & JohnsonErleada$2,600$826,33954 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$434$380,908176 claims
BayerNubeqa$695$275,10421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.

Other urology in Ocala

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →